XML 140 R83.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Segment information (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Operating Segments [Abstract] |
Schedule of Segment Results | The table below shows Sanofi’s segment results for the years ended December 31, 2024, December 31, 2023 and December 31, 2022:
| 2024
(€ million) | Biopharma | Other | Total
| 2024 | Change vs. 2023 on a reported basis (IFRS) | Change vs. 2023 at constant exchange rates (non- IFRS) | 2024 | Change vs. 2023 on a reported basis (IFRS) | Change vs. 2023 at constant exchange rates (non- IFRS) | 2024 | Change vs. 2023 on a reported basis (IFRS) | Change vs. 2023 at constant exchange rates (non- IFRS)
Net sales | 41,081 | 8.6% | 11.3% | — |  |  | 41,081 | 8.6% | 11.3%
Other revenues | 2,866 | (18.2%) | (16.3%) | 339 | 14.5% | 23.3% | 3,205 | (15.7%) | (13.3%)
Cost of sales | (12,973) | 4.5% | 5.7% | (222) | 8.8% | 20.1% | (13,195) | 4.6% | 6.0%
Research and development expenses | (7,393) | 13.7% | 14.6% | (1) | (50.0%) | (50.0%) | (7,394) | 13.6% | 14.6%
Selling and general expenses | (9,113) | 2.9% | 4.6% | (70) | (11.4%) | (3.8%) | (9,183) | 2.8% | 4.5%
Other operating income and expenses | (3,305) |  |  | 12 |  |  | (3,293) |  |
Share of profit/(loss) from investments accounted for using the equity method | 136 |  |  | — |  |  | 136 |  |
Net income attributable to non-controlling interests | (14) |  |  | — |  |  | (14) |  |
Business operating income | 11,285 | 1.2% | 7.3% | 58 | 152.2% | 160.9% | 11,343 | 1.5% | 7.6%
As % of net sales | 27.5% |  |  |  |  |  | 27.6% |  |
| 2023(a)
(€ million) | Biopharma | Other | Total
Net sales | 37,817 | — | 37,817
Other revenues | 3,505 | 296 | 3,801
Cost of sales | (12,415) | (204) | (12,619)
Research and development expenses | (6,505) | (2) | (6,507)
Selling and general expenses | (8,854) | (79) | (8,933)
Other operating income and expenses | (2,476) | 12 | (2,464)
Share of profit/(loss) from investments accounted for using the equity method | 101 | — | 101
Net income attributable to non-controlling interests | (18) | — | (18)
Business operating income | 11,155 | 23 | 11,178
(a)Figures for the comparative period (2023) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
| 2022(a)(b)
(€ million) | Biopharma | Other | Total
Net sales | 37,651 | — | 37,651
Other revenues | 2,534 | 376 | 2,910
Cost of sales | (11,682) | (197) | (11,879)
Research and development expenses | (6,499) | (2) | (6,501)
Selling and general expenses | (8,536) | (203) | (8,739)
Other operating income and expenses | (764) | 55 | (709)
Share of profit/(loss) from investments accounted for using the equity method | 76 | — | 76
Net income attributable to non-controlling interests | (16) | — | (16)
Business operating income | 12,764 | 29 | 12,793
(a) Figures for the comparative period (2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. (b) 2022 business operating income has been recast from the amount previously reported to include the one-time income of €952 million from the Libtayo transaction (€706 million net of tax).
Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method | The table below, presented in compliance with IFRS 8, shows a reconciliation between aggregated “Business operating income” for the segment and Income before tax and investments accounted for using the equity method:
(€ million) | 2024 | 2023(a) | 2022(a)(h)
Business operating income | 11,343 | 11,178 | 12,793
Share of profit/(loss) from investments accounted for using the equity method(b) | (136) | (101) | (76)
Net income attributable to non-controlling interests(c) | 14 | 18 | 16
Amortization and impairment of intangible assets(d) | (1,997) | (2,807) | (1,375)
Fair value remeasurement of contingent consideration | (96) | (93) | 27
Expenses arising from the impact of acquisitions on inventories(e) | (10) | (9) | (3)
Restructuring costs and similar items(f) | (1,396) | (1,030) | (1,077)
Other gains and losses, and litigation(g) | (470) | (196) | (143)
Operating income | 7,252 | 6,960 | 10,162
Financial expenses | (1,073) | (1,293) | (430)
Financial income | 519 | 584 | 205
Income before tax and investments accounted for using the equity method | 6,698 | 6,251 | 9,937
(a)Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. (b)Joint ventures and associates with which Sanofi has entered into a strategic alliance. (c)Excludes (i) restructuring costs and (ii) other adjustments attributable to non-controlling interests. (d)For 2024, this line includes a net impairment charge of €248 million mainly due to a recognition of impairment losses of €640 million against on various research and development projects – including a €239 million loss resulting from the decision taken in February 2025 to discontinue a phase 3 clinical study investigating of a vaccine candidate to prevent invasive E.coli disease - partially offset by impairment losses reversals, recognized in connection with the disposals of the ProXTen platform and Enjaymo, for €225 million and €167 million respectively. For 2023, this amount mainly comprises an impairment loss of €833 million, reflecting the impact of the strategic decision to de-prioritize certain R&D programs, in particular those related to the NK Cell and ProXTen technology platforms. For 2022, this line includes a reversal of €2,154 million on Eloctate franchise products following FDA approval of ALTUVIIIO on February 22, 2023, partially offset by an impairment loss of €1,586 million on intangible assets relating to SAR444245 (non- alpha interleukin-2). (e)This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date. (f) See note D.27. (g)See note D.28. (h) 2022 business operating income has been recast from the amount previously reported to include the one-time income of €952 million from the Libtayo transaction (€706 million net of tax).
Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment | Acquisitions of intangible assets and property, plant and equipment correspond to acquisitions paid for during the period.
| Biopharma
(€ million) | 2024 | 2023 | 2022
Investments accounted for using the equity method (a) | 234 | 234 | 248
Acquisitions of property, plant and equipment | 1,733 | 1,619 | 1,529
Acquisitions of other intangible assets | 1,462 | 1,287 | 574
(a)Carrying amount at the end of the reporting period.
Summary of Geographical Information on Net Sales and Non-Current Assets | The geographical information on net sales provided below is based on the geographical location of the customer. In accordance with IFRS 8, the non-current assets reported below exclude right-of-use assets relating to leases as determined under IFRS 16, investments accounted for using the equity method, other non-current assets, non-current income tax assets, and deferred tax assets.
| 2024
(€ million) | Total | Europe | of which France | United States | Other countries
Net sales | 41,081 | 9,027 | 1,814 | 19,986 | 12,068
Non-current assets: |  |  |  |  |
•property, plant and equipment owned | 10,091 | 5,550 | 3,112 | 2,411 | 2,130
•goodwill | 43,384 | — | — | — | —
▪other intangible assets | 22,629 | 3,307 | — | 18,711 | 611
(€ million) | 2023
Total | Europe | of which France | United States | Other countries
Net sales(a) | 37,817 | 8,816 | 1,910 | 17,262 | 11,739
Non-current assets: |  |  |  |  |
•property, plant and equipment owned | 10,160 | 5,659 | 3,085 | 2,322 | 2,179
•goodwill | 49,404 | — | — | — | —
•other intangible assets | 24,319 | 5,566 | — | 17,850 | 903
(a)Figures for 2023 have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
(€ million) | 2022
Total | Europe | of which France | United States | Other countries
Net sales(a) | 37,651 | 8,490 | 1,830 | 16,986 | 12,175
Non-current assets: |  |  |  |  |
•property, plant and equipment owned | 9,869 | 5,365 | 2,875 | 2,457 | 2,047
•goodwill | 49,892 | — | — | — | —
•other intangible assets | 21,640 | 6,257 | — | 14,174 | 1,209
(a)Figures for 2022 have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.

X
- Definition The disclosure of geographical information. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2023-01-01 -Paragraph 33 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_DisclosureOfGeographicalAreasExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of operating segments. [Refer: Operating segments [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2023-01-01 -Paragraph 23 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_DisclosureOfOperatingSegmentsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of acquisitions of property plant and equipment and other intangible assets and carrying amount of investments in associates and joint ventures by operating segment. + References No definition available. + Details
Name: | sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock
Namespace Prefix: | sny_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of operating segments reconciling items. + References No definition available. + Details
Name: | sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock
Namespace Prefix: | sny_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Operating Segments [Abstract] + References No definition available. + Details
Name: | sny_OperatingSegmentsAbstract
Namespace Prefix: | sny_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration